Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

139 results about "Castration Resistance" patented technology

A finding indicating that a prostate carcinoma continues to grow despite the surgical removal of the testes or medical intervention to block androgen production.

Compounds and methods for the targeted degradation of androgen receptor

This disclosure pertains to methods of treating prostate cancer in a subject in need thereof, including, for example, metastatic prostate cancer, castrate-resistant prostate cancer, and metastatic castrate-resistant prostate cancer, wherein the method comprises administering to the subject a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, and further comprises a step of discontinuing or reducing the administration of a CYP3A inhibitor or inducer, an efflux transporter substrate or inhibitor, or an uptake transporter substrate or inhibitor, to the subject prior to initiating administration of Compound Aor the pharmaceutically acceptable salt thereof.
Owner:ARVINAS OPERATIONS INC

Compound, composition comprising same, and use thereof

Provided are a compound, or a stereoisomer, or pharmaceutically acceptable salt, or deuterated compound, or tautomer, or polymorphic substance, or solvate, or N-oxide, or isotope labeled compound, or metabolite, or prodrug thereof, and a use thereof. The structure of the compound is as shown in formula 0, and the compound serves as an AR regulator and has better castration-resistant prostate cancer cell proliferation inhibition activity, better AR protein degradation activity, and better oral bioavailability.
Owner:QINGDAO PUTAIKE BIOMEDICAL TECHNOLOGY CO LTD

Method for treating prostate cancer

A method for treating prostate cancer; specifically, the use of a compound of formula I or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating metastatic castration-resistant prostate cancer.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

CBLN1 monoclonal antibody and application

The invention discloses a CBLN1 monoclonal antibody and an application thereof. The CBLN1 monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the light chain variable region comprises three complementary determining regions CDR1, CDR2 and CDR3, the amino acid sequence of the CDR1 is shown as SEQ ID NO.1, the amino acid sequence of the CDR2 is KVS, and the amino acid sequence of the CDR3 is shown as SEQ ID NO.2; the amino acid sequences of three complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region are respectively as shown in SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5. The invention also discloses a preparation method of the monoclonal antibody and application of the monoclonal antibody in preparation of drugs for treating breast cancer and prostate cancer, especially castration-resistant prostate cancer and androgen receptor dependent prostate cancer. The CBLN1 specific monoclonal antibody can be used for functionally blocking the CBLN1 and improving the inhibition of a tumor immune microenvironment.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Methods of treating prostate cancer

The present disclosure relates to a method of treating prostate specific membrane antigen (PSMA) positive progressive metastatic castration resistant prostate cancer (mCRPC) by administering a therapeutically effective amount of a PSMA binding radioligand therapy (RLT) agent, preferably [177Lu] Lu-PSMA-617 (lutetium (177Lu) vevovortitide Tailaracetam), to a taxane primarily treated patient whose disease progresses after receiving a second generation ARPI.
Owner:NOVARTIS AG

Multi-omic prediction model for metastatic prostate cancer

PendingUS20240379235A1Health-index calculationMedical automated diagnosisSexual hormonesHormone sensitive prostate cancer
Disclosed is a method for predicting a clinical outcome in a metastatic prostate cancer patient based on measurements of multi-omic features of the patient. A weighting model is selected based on the state of the metastatic prostate cancer (a metastatic hormone sensitive prostate cancer (mHSPC) state or a metastatic castrate resistant prostate cancer (mCRPC) state) and on a clinical outcome of interest. The weighting model maps weights to a series of features (including genetic markers and lipid markers) with respect to the clinical outcome of interest. The weights are generated using a machine learning process that utilizes a training dataset that associates the features of multiple historic metastatic prostate cancer patients with recorded clinical outcomes of those patients. A predictive model generates a probability score for the patient indicating the likelihood of occurrence of the clinical outcome of interest.
Owner:UNIV OF UTAH RES FOUND

Bavdegalutamide for treating prostate cancer without ar l702h mutation

This disclosure pertains to methods of treating prostate cancer in a subject with one or more mutations in the Androgen Receptor ligand binding domain, including, for example, metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, progressive metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, metastatic castrate-sensitive prostate cancer, prostate cancer naïve to novel hormonal agents (NHAs), metastatic prostate cancer naïve NHAs, castrate-resistant prostate cancer naïve to NHAs, castrate-sensitive prostate cancer naïve to NHAs, metastatic castrate-resistant prostate cancer naïve to NHAs, and metastatic castrate-sensitive prostate cancer naïve to NHAs, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof.
Owner:ARVINAS OPERATIONS INC

Tumor prognosis risk prediction method based on multi-modal medical image fusion

The invention relates to the technical field of medical image processing, in particular to a tumor prognosis risk prediction method based on multi-modal medical image fusion, which comprises the following steps: firstly, acquiring patient data, and preprocessing the patient data; the patient data comprises an MRI image and a WSI image of the prostate cancer patient; then, MRI image features and WSI image features are respectively extracted from the preprocessed data; next, the MRI image features and the WSI image features are fused, and fused features are obtained; and finally, inputting the fusion features into a deep learning prediction model, and outputting a risk probability value that the patient develops into CRPC. The tumor prognosis risk prediction method based on multi-modal medical image fusion provided by the invention can effectively predict the risk of prostate cancer patients developing into castration-resistant prostate cancer after androgen deprivation treatment.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

BRCA2 protein targeting polypeptide, application thereof and medicine for treating prostatic cancer

The invention belongs to the technical field of protein polypeptides, and particularly relates to a polypeptide targeting BRCA2 protein, application of the polypeptide and a medicine for treating prostatic cancer. The amino acid sequence of the polypeptide is shown as SEQ ID NO.1, the polypeptide has high binding capacity with BRCA2 protein, cell proliferation and tumor growth can be effectively inhibited when the polypeptide is delivered to prostatic cancer, and meanwhile the polypeptide has the capacity of degrading BRCA2 in a targeted mode. The combined application of the polypeptide and the PARP inhibitor can enhance the sensitivity of prostate cancer cells to the PARP inhibitor. Therefore, the polypeptide can be applied to preparation of a medicine for treating metastatic castration-resistant prostate cancer or preparation of a reagent for degrading the BRCA2 protein. The BRCA2 targeting PROTAC medicine can provide a new treatment strategy for prostatic cancer treatment, and the PARP targeting inhibitor is combined to provide a PARP inhibitor synthesis lethal treatment effect for metastatic castration resistant prostatic cancer patients.
Owner:THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV

Traditional Chinese medicine composition for treating prostatic cancer as well as preparation method and application of traditional Chinese medicine composition

The invention belongs to the technical field of medicine and health, and particularly relates to a traditional Chinese medicine composition for treating prostatic cancer and a preparation method and application thereof. The traditional Chinese medicine composition comprises the following raw materials: raw radix astragali, radix sophorae flavescentis, yam rhizome, turmeric, cowherb seed and rhizoma anemarrhenae, and can prevent, treat and relieve prostatic cancer through the mutual synergistic effect of the active ingredients of various traditional Chinese medicines; the traditional Chinese medicine composition can reduce tPSA of patients, relieve vasomotor symptoms and mental and psychological symptoms, control blood fat, improve immune functions and relieve fatigue conditions, is suitable for long-term use of prostate cancer patients, and is especially suitable for castration-resistant prostate cancer patients or combined application with endocrine drugs.
Owner:THE FIRST AFFILIATED HOSPITAL OF TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE

Application of new Lnc-FLJ in the treatment of castration-resistant prostate cancer

The present invention belongs to the field of biomedicine technology, and relates to the application of the Lnc-FLJ gene in the treatment of castration-resistant prostate cancer. The application of the Lnc-FLJ gene inhibitor in the preparation of prostate cancer drugs. The present invention discovered for the first time that Lnc-FLJ can inhibit the proliferation and autophagy of castration-resistant prostate cancer. Lnc-FLJ is more highly expressed in castration-resistant prostate cancer cells and prostate cancer tissues with higher malignancy. Inhibiting Lnc-FLJ can inhibit the occurrence and development of castration-resistant prostate cancer. The preparation of Lnc-FLJ small molecule inhibitor shRNA is used to treat castration-resistant prostate cancer and cancer insensitive to enzalutamide, thereby inhibiting the AR signaling pathway. The present invention provides new ideas for further studying the pathogenesis of castration-resistant prostate cancer and the function of the Lnc-FLJ gene, and provides a new direction for the development of castration-resistant prostate cancer drugs.
Owner:重庆医科大学国际体外诊断研究院

Methods and compositions for treating androgen receptor deficient, androgen receptor low, and castration-resistant prostate cancers

Methods and compositions for treatment of prostate cancers, such as androgen receptor (AR) deficient and androgen receptor (AR) low cancers, are disclosed. The methods include administration of an agent that inhibits activity of eIF4F or an agent that disrupts the eIF4F translation-initiation complex (composed of eIF4E, eIF4A, and eIF4G).
Owner:FRED HUTCHINSON CANCER CENT

Methods of treating metastatic castration resistant prostate cancer with bispecific anti-psma x anti-CD28 antibodies

The present disclosure provides methods for treating prostate cancer or metastatic castration-resistant prostate cancer, reducing the severity of prostate cancer or metastatic castration-resistant prostate cancer, or inhibiting the growth of prostate cancer or metastatic castration-resistant prostate cancer. The methods of the present disclosure comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody, or antigen-binding fragment thereof, that specifically binds to prostate specific membrane antigen (PSMA) and CD28, as a monotherapy or in combination with an anti-PD1 antibody.
Owner:REGENERON PHARMACEUTICALS INC

Targeting ADAMTS1 to inhibit castration-resistant prostate cancer proliferation and metastasis by promoting collagen degradation

The invention belongs to the technical field of cancer treatment, and discloses a method for inhibiting castration-resistant prostate cancer proliferation and metastasis by promoting collagen degradation through targeting ADAMTS1. According to the method, ADAMTS1 is determined to be a mechanism key point for linking epigenetic reprogramming with biomechanical microenvironment destruction. The ADAMTS1 is reactivated to degrade a collagen-rich matrix, the FAK / MAPK mechanical transduction signaling pathway is inhibited, and the epithelial-mesenchymal transition (EMT) is reversed. The strategy not only achieves more than 90% of tumor inhibition effect, but also exhausts immunosuppressive macrophages and regulatory T cells to reverse immunosuppression by enhancing toxic CD8 + T cell infiltration. The research determines that epigenetic-ECM coevolution is a symbolic feature of CRPC, and provides a reasonably designed combination therapy for treating castration-resistant prostate cancer.
Owner:THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV

Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment

Methods of treating non-metastatic castration-resistant prostate cancer in a subject having severe liver damage are provided.SOLUTION: Provided are methods of treating non-metastatic castration-resistant prostate cancer in a subject with severe hepatic impairment with an androgen receptor inhibitor comprising 4 - [7 - (6-cyano-5-trifluoromethylpyridin-3-yl) - 8-oxo-6-thioxo-5, 7-diazaspiro [3.4] oct-5-yl] - 2-fluoro-N-methylbenzamide (apalutamide).SELECTED DRAWING: None
Owner:ARAGON PHARMACEUTICALS INC

Pharmaceutical composition for resisting castration-resistant prostate cancer cells and application thereof

The present invention relates to a composition for the treatment of castration resistant prostate cancer, the composition comprising (i) a first active ingredient comprising a CDK9 degrading agent; and (ii) a second active ingredient, wherein the second active ingredient comprises olaparib. The effects of inhibiting tumor cell proliferation and promoting cell apoptosis of the composition are obviously higher than those of a single drug under the same dosage.
Owner:SHANGHAI PUDONG HOSPITAL

Methods of treating prostate cancer

This is a method for treating prostate cancer. Specifically, it involves the use of the compound shown in Formula I or a pharmaceutically acceptable salt thereof in the manufacture of a drug for treating metastatic castration-resistant prostate cancer. [Formula 1] JPEG2026521901000005.jpg32155
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and HRR alterations

PendingAU2023214795B2PrednisoloneEfficacy
The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median radiographic progression-free survival (rPFS).
Owner:JANSSEN PHARMA NV

Gene marker for predicting castration resistance and prognosis risk of hormone-sensitive prostate cancer and application of gene marker

The invention discloses a gene marker for predicting castration resistance and prognosis risk of hormone-sensitive prostate cancer, the gene marker comprises at least one of PRR7, REXO2, SKP1, MXD3, SPAG5, DHX16, NASP, TSPAN6, CCDC127 and BCAS1, and the gene marker is also used for constructing an evaluation model (LLPS-related prostate risk score, LPRS) for predicting castration resistance and prognosis risk of hormone-sensitive prostate cancer. The model can accurately predict castration resistance and death risk of hormone-sensitive prostate cancer, multi-factor Cox regression analysis finds that LPRS is an independent prognosis index of three prostate cancer queues, and further meta analysis results combine HR to 1.44 (95% CI = 1.11-1.89), that is, the risk of disease progression, recurrence or death is increased by 44% every time the LPRS is increased by one unit.
Owner:SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG PROVINCIAL HOSPITAL)

Abiragentian acetate liposome composition and preparation method thereof

The invention belongs to the field of new drugs, and discloses an abiraterone acetate liposome composition and a preparation method thereof, the composition comprises abiraterone acetate, phospholipid, cholesterol, cholate and a protective agent, a nano liposome is adopted for solubilization, and cholate molecules are embedded into a liposome membrane to form a flexible liposome with high deformability and permeability. The bile salt liposome can improve the solubility of abiraterone acetate in water, resist attack of gastrointestinal tract physiological bile salt, maintain relative integrity of a liposome membrane, open tight connection of gastrointestinal epithelial cells, promote intestinal mucosa absorption and doubly improve oral bioavailability. The obtained abietin acetate lipidosome can be used for treating metastatic castration-resistant prostate cancer, the preparation process is simple, amplification is easy, and freeze-dried powder is high in stability and convenient to store and transport, so that the abietin acetate lipidosome has extremely high industrial application value.
Owner:UNIV OF JINAN +1

Application of nefenavir

The invention relates to the technical field of biological medicine, and particularly discloses application of nefenavir. Nefinavir is used for preparing a medicine for treating or preventing castration-resistant prostate cancer, and the medicine can specifically up-regulate expression of DHCR7, induce DNA damage of tumor cells and activate a cell cycle arrest pathway mediated by periodic protein of the cells so as to inhibit key biological processes such as proliferation of the tumor cells, cholesterol metabolism and the like; especially, formation and amplification of multinuclear giant cells in castration-resistant prostate cancer can be effectively inhibited by up-regulating expression of DHCR7, so that malignant progression of multinuclear giant cell mediated tumors and treatment of drug resistance are blocked. Finally, the castration-resistant prostate cancer is prevented and treated, and the technical bottlenecks that an existing castration-resistant prostate cancer treatment means is limited in curative effect, and the drug resistance and metastasis capability mediated by multinuclear giant cells are difficult to inhibit in a targeted manner are solved.
Owner:THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV

Use of mylk3 gene inhibitor in preparation of drug for treating castration-resistant prostate cancer

The application belongs to the technical field of biological medicine, and discloses application of a MYLK3 gene inhibitor in preparation of a drug for treating castration-resistant prostate cancer. The biological function of MYLK3 in prostate cancer is confirmed for the first time, an intervention means with the gene as a target point is provided, and it is confirmed that the MYLK3 inhibitor can improve the sensitivity of castration-resistant prostate cancer to androgen receptor antagonists. A gene therapy drug with the human MYLK3 gene as a treatment target point is specially provided, which is suitable for the treatment of prostate cancer (especially castration-resistant prostate cancer), and can also be combined with other targeted drugs to improve the treatment effect. By designing a reasonable RNAi target sequence for the target gene, a retrovirus vector plasmid containing the target sequence is successfully constructed, which has a significant inhibitory effect on the proliferation ability of prostate cancer cells, and significantly increases the sensitivity of prostate cancer cells to AR antagonists.
Owner:GUANGZHOU CUNZHONG TECHNOLOGY SERVICE CO LTD

Application of Se-coated SiO2-DTX in preparation of product for treating prostate cancer or castration-resistant prostate cancer

The invention belongs to the technical field of tumor resistance, and particularly relates to application of Se-coated SiO2-DTX in preparation of a product for treating prostate cancer or castration-resistant prostate cancer. The invention relates to an application of a tyrosine phosphorylation inhibitor or / and cPAP (c-Phosphorylation Inhibitor) for preventing or treating prostatic cancer or castration-resistant prostatic cancer, wherein the tyrosine phosphorylation inhibitor comprises at least one of Y < 279 >, Y < 357 > and Y < 488 >, and the tyrosine phosphorylation inhibitor can be used for preventing or treating prostatic cancer or castration-resistant prostatic cancer. According to the invention, Se-coated SiO2 and docetaxel are combined for use, so that not only can the direct anticancer effect of selenium in Se-coated SiO2 be played, but also the killing effect of the chemotherapeutic drug docetaxel on cancer cells can be improved, and the application has important clinical significance.
Owner:BEIJING FRIENDSHIP HOSPITAL CAPITAL MEDICAL UNIV

Methods of treating metastatic castration resistant prostate cancer with bispecific anti-PSMA x anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies

The present disclosure provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., prostate cancer or metastatic castration-resistant prostate cancer). The methods of the present disclosure comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody, or antigen-binding fragment thereof, that specifically binds prostate specific membrane antigen (PSMA) and CD3, either alone or in combination with an antibody, or antigen-binding fragment thereof, that specifically binds to programmed death 1 (PD-1) receptor.
Owner:REGENERON PHARMACEUTICALS INC

Blood diagnosis marker for identifying good prognosis prostate cancer and metastatic castration-resistant prostate cancer and application of blood diagnosis marker

The invention provides a blood diagnosis marker for identifying prostate cancer with good prognosis and metastatic castration-resistant prostate cancer and application of the blood diagnosis marker, and relates to the technical field of prostate cancer risk assessment. The blood diagnosis markers are NCKAP1, ERCC1, ZBTB46, PAQR7, ARMC8, PAQR8, LRRN4, NOG, LRRC47, CDKN2D, CLEC1B, STARD7 and ZSCAN2, and the blood diagnosis markers are used for diagnosis of the blood. The marker can be used for preparing a kit and a risk assessment chip for identifying prostate cancer with good prognosis and metastatic castration-resistant prostate cancer. According to the invention, the defects in the prior art are overcome, and a good and reliable basis is provided for identifying the prostate cancer with good prognosis and the metastatic castration-resistant prostate cancer by determining the blood diagnosis marker.
Owner:FUYANG PEOPLES HOSPITAL